Literature DB >> 4073853

Biotinidase deficiency: initial clinical features and rapid diagnosis.

B Wolf, G S Heard, K A Weissbecker, J R McVoy, R E Grier, R T Leshner.   

Abstract

Biotinidase deficiency is the primary defect in most individuals with late-onset multiple carboxylase deficiency. We have reviewed the presenting clinical features of 31 children with the disorder. Seizures, either alone or with other neurological or cutaneous findings, are the most frequent initial symptom observed. Other neurological symptoms, such as hypotonia, ataxia, hearing loss, optic atrophy, and developmental delay, are seen, in addition to skin rash and alopecia. The disorder is also characterized by ketolactic acidosis and organic aciduria. Biotinidase activity may be diagnosed using a simple, rapid, semiquantitative colorimetric procedure. Samples of whole blood spotted on the same filter paper used by most states to screen for phenylketonuria and other inborn errors of metabolism may be sent to an appropriate reference laboratory. None of the common anticonvulsants or sedatives used to treat newborns and children interfere with the test. Because biotinidase deficiency can be treated readily with biotin, this disorder should be considered in children with infantile seizures, especially in the presence of other characteristic neurological or cutaneous features.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4073853     DOI: 10.1002/ana.410180517

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

1.  Novel mutations cause biotinidase deficiency in Turkish children.

Authors:  R J Pomponio; T Coskun; M Demirkol; A Tokatli; I Ozalp; G Hüner; T Baykal; B Wolf
Journal:  J Inherit Metab Dis       Date:  2000-03       Impact factor: 4.982

Review 2.  Early-onset epileptic encephalopathies and the diagnostic approach to underlying causes.

Authors:  Su-Kyeong Hwang; Soonhak Kwon
Journal:  Korean J Pediatr       Date:  2015-11-22

3.  Influences of dietary biotin and avidin on growth, survival, deficiency syndrome and hepatic gene expression of juvenile Nile tilapia Oreochromis niloticus.

Authors:  Pallab Kumer Sarker; Rodrigue Yossa; Santhosh Karanth; Marc Ekker; Grant W Vandenberg
Journal:  Fish Physiol Biochem       Date:  2012-01-25       Impact factor: 2.794

4.  Development and characterization of a mouse with profound biotinidase deficiency: a biotin-responsive neurocutaneous disorder.

Authors:  Kirit Pindolia; Megan Jordan; Caiying Guo; Nell Matthews; Donald M Mock; Erin Strovel; Miriam Blitzer; Barry Wolf
Journal:  Mol Genet Metab       Date:  2010-10-13       Impact factor: 4.797

5.  "Cerebral" lactic acidosis and biotinidase deficiency.

Authors:  J Jaeken; P Casaer
Journal:  Eur J Pediatr       Date:  1988-11       Impact factor: 3.183

6.  "Think metabolic" in adults with diagnostic challenges: Biotinidase deficiency as a paradigm disorder.

Authors:  Barry Wolf
Journal:  Neurol Clin Pract       Date:  2017-12

7.  High frequencies of biotinidase (BTD) gene mutations in the Hungarian population.

Authors:  Ilona Milánkovics; Krisztina Németh; Csilla Somogyi; Agnes Schuler; György Fekete
Journal:  J Inherit Metab Dis       Date:  2010-06-15       Impact factor: 4.982

8.  Normalisation of severe cranial CT scan abnormalities after biotin in a case of biotinidase deficiency.

Authors:  H D Bakker; M Westra; W C Overweg-Plandsoen; G van Waveren; J H Sillevis Smitt; N G Abeling; R J Wanders; R B Schutgens; A H van Gennip
Journal:  Eur J Pediatr       Date:  1994-11       Impact factor: 3.183

Review 9.  Epilepsy and inborn errors of metabolism in adults: a diagnostic approach.

Authors:  F Sedel; I Gourfinkel-An; O Lyon-Caen; M Baulac; J-M Saudubray; V Navarro
Journal:  J Inherit Metab Dis       Date:  2007-10-22       Impact factor: 4.982

10.  A biotinidase Km variant causing late onset bilateral optic neuropathy.

Authors:  V T Ramaekers; T M Suormala; M Brab; R Duran; G Heimann; E R Baumgartner
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.